Unknown

Dataset Information

0

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.


ABSTRACT: Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in clinical trials. For LC with Epidermal Growth Factor Receptor (EGFR) mutations, there is no clear association of this mutation with age. Geriatric assessments (GAs) and a multidisciplinary approach are essential for defining the optimal treatment. In this consensus, a group of experts selected from the Oncogeriatrics Section of the Spanish Society of Medical Oncology (Sección de Oncogeriatría de la Sociedad Española de Oncología Médica-SEOM), the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón-GECP) and the Association for Research on Lung Cancer in Women (Asociación para la Investigación del Cáncer de Pulmón en Mujeres-ICAPEM) evaluate the scientific evidence currently available and propose a series of recommendations to optimize the management of older adult patients with advanced LC with EGFR mutations.

SUBMITTER: Nadal E 

PROVIDER: S-EPMC10514135 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer.

Nadal Ernest E   Oré-Arce Martín M   Remon Jordi J   Bernabé-Caro Reyes R   Covela-Rúa Marta M   de Castro-Carpeño Javier J   Massutí-Sureda Bartomeu B   Guillot-Morales Mónica M   Majem Margarita M   Maestu-Maiques Inmaculada I   Morilla-Ruíz Idoia I   Gironés Regina R  

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20230811 11


Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in clinical trials. For LC with Epidermal Growth Factor Receptor (EGFR) mutations, there is no clear association of this mutation with age. Geriatric assessments (GAs) and a multidisciplinary approach are essential for defining the optimal treatment. In this cons  ...[more]

Similar Datasets

| S-EPMC7253730 | biostudies-literature
| S-EPMC9813031 | biostudies-literature
| S-EPMC8512472 | biostudies-literature
| S-EPMC8512462 | biostudies-literature
| S-EPMC8971510 | biostudies-literature
| S-EPMC10275278 | biostudies-literature
| S-EPMC5879504 | biostudies-literature
| S-EPMC10413514 | biostudies-literature
| S-EPMC11787051 | biostudies-literature
| S-EPMC7818260 | biostudies-literature